Search result for "Solr search content"
Search Result for "*:*"
Clinical Trial
A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase – Chronic Myelogenous Leukemia (ASC2ESCALATE) (CTMS# 23-0101)
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP-binding site TKI with discontinuation due to treatment failure, warning, or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.
National Cancer Institute Designation
National Cancer Institute Designation
Our Cancer Clinical Trials
Our Cancer Clinical Trials
Cancer Genetics Program
Cancer Genetics Program
Blood Disorder (Hematology) Program
Blood Disorder (Hematology) Program
Our Cancer Programs
Our Cancer Programs